NCT06237426: An ongoing trial by Transcend Therapeutics
This trial is ongoing. It must report results 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06237426 |
|---|---|
| Title | A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments With Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD]) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 6, 2024 |
| Completion date | Oct. 6, 2025 |
| Required reporting date | Oct. 6, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |